Cytokinetics (CYTK) and FuboTV (FUBO) Options Volume Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: NASDAQ.COM
- Cytokinetics Options Activity: Cytokinetics Inc (CYTK) has seen an options volume of 11,482 contracts today, representing approximately 1.1 million underlying shares, which is 51.5% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Call Option Volume: Within CYTK, the $70 strike call option expiring on May 15, 2026, has traded 5,012 contracts, representing about 501,200 shares, suggesting increased investor expectations for the stock's upward movement.
- FuboTV Options Activity: FuboTV Inc (FUBO) has recorded an options volume of 51,955 contracts today, equating to approximately 5.2 million underlying shares, which constitutes 50.5% of its average daily trading volume over the past month, reflecting strong market interest in its stock.
- High Put Option Volume: For FUBO, the $2.50 strike put option expiring on January 16, 2026, has seen 28,711 contracts traded, representing around 2.9 million shares, indicating investor concerns about potential declines in the stock's future value.
Analyst Views on CYTK
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
